190 related articles for article (PubMed ID: 33586698)
1. Identifying the role of apolipoprotein A-I in prostate cancer.
Wang J; Xu LF; Liu C; Huang T; Liang CZ; Fan YD
Asian J Androl; 2021; 23(4):400-408. PubMed ID: 33586698
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
[TBL] [Abstract][Full Text] [Related]
6. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
8. Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis.
Huang W; Eickhoff JC; Mehraein-Ghomi F; Church DR; Wilding G; Basu HS
Prostate; 2015 Aug; 75(11):1150-9. PubMed ID: 25893668
[TBL] [Abstract][Full Text] [Related]
9. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
11. The role of HOXC6 in prostate cancer development.
Hamid AR; Hoogland AM; Smit F; Jannink S; van Rijt-van de Westerlo C; Jansen CF; van Leenders GJ; Verhaegh GW; Schalken JA
Prostate; 2015 Dec; 75(16):1868-76. PubMed ID: 26310814
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
13. Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.
Jain P; Clermont PL; Desmeules F; Zoubeidi A; Neveu B; Pouliot F
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626088
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
Int J Cancer; 2008 Dec; 123(11):2636-43. PubMed ID: 18767043
[TBL] [Abstract][Full Text] [Related]
15. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.
Xu B; Teng LH; Silva SD; Bijian K; Al Bashir S; Jie S; Dolph M; Alaoui-Jamali MA; Bismar TA
Cancer Med; 2014 Feb; 3(1):14-24. PubMed ID: 24402972
[TBL] [Abstract][Full Text] [Related]
16. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
19. Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
Mitsui Y; Arichi N; Hiraki M; Harada Y; Yasumoto H; Shiina H
Urol J; 2015 Jul; 12(3):2165-72. PubMed ID: 26135933
[TBL] [Abstract][Full Text] [Related]
20. Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.
Biggs CN; Siddiqui KM; Al-Zahrani AA; Pardhan S; Brett SI; Guo QQ; Yang J; Wolf P; Power NE; Durfee PN; MacMillan CD; Townson JL; Brinker JC; Fleshner NE; Izawa JI; Chambers AF; Chin JL; Leong HS
Oncotarget; 2016 Feb; 7(8):8839-49. PubMed ID: 26814433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
